Relay Therapeutics (RLAY) Operating Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Operating Expenses data on file, last reported at $81.6 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 11.84% year-over-year to $81.6 million in Q1 2026; TTM through Mar 2026 was $307.1 million, a 18.02% decrease from a year earlier, with the FY2025 full-year figure at $318.1 million, down 16.83% from the prior year.
• Operating Expenses for Q1 2026 stood at $81.6 million, up from $67.6 million in the prior quarter.
• Over the last five years, Operating Expenses for RLAY reached as high as $106.2 million in Q2 2023 and fell as low as $63.1 million in Q1 2022.
• Historically, Operating Expenses has averaged $87.1 million across 5 years, with a median of $86.2 million in 2022.
• Across the five-year window, Operating Expenses tumbled 59.79% in 2022 and surged 60.6% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $73.1 million in 2022, then grew by 26.11% to $92.2 million in 2023, then declined by 7.83% to $85.0 million in 2024, then fell by 20.42% to $67.6 million in 2025, then gained by 20.64% to $81.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $81.6 million in Q1 2026, $67.6 million in Q4 2025, and $80.4 million in Q3 2025.